JOHN KIRKWOOD to Intention to Treat Analysis
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Intention to Treat Analysis.
Connection Strength
0.055
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18.
Score: 0.031
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30; 364(26):2507-16.
Score: 0.024